Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANH in Cytoreductive Surgery for Ovarian Cancer
NCT06290193Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2024
- Primary completion
- Feb 2029
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Rate of allogenic red blood cell transfusions at 30 days. Started Feb 2024; status: recruiting.
Beyond the preview
Go deeper on NCT06290193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06290193.